We know that we won’t discover everything inside our own labs and that we need to partner with other companies, academic institutions and research charities.
Working with partners to deliver the next generation of transformational medicines and vaccines
This is especially true in areas where research is particularly difficult, for example in the science around antibiotics, and where illnesses are proving particularly hard to understand, like Alzheimer’s disease.
We currently have research collaborations with thousands of external organisations, including other companies, academic institutions and research charities. And we’re adding to this number every year. We’re also partnering with governments, charities and other organisations on innovative funding mechanisms, enabling us to share the costs of research into diseases and illnesses that are proving particularly difficult to solve.
And in the case of illnesses that have a disproportionate impact on developing countries – like malaria or tuberculosis – we have a different challenge: these countries have a pressing need for new treatments, yet they are the very countries that can least afford to pay for them.
In these regions, we need to come up with radically different ways of supporting our R&D. To do this, we’re stimulating innovation in new ways, looking outside our own labs and opening up access to our expertise, our facilities and even our intellectual property.
Find out more on how we are tackling diseases of the developing world: https://www.gsk.com/en-gb/research/our-approach/open-innovation/diseases-of-the-developing-world/